In contrast, Eli Lilly (NYSE: LLY) and Hims & Hers Health (NYSE: HIMS) both jumped on today's news. They rose 2.7% and 7%, ...
Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved promising weight reduction in a ...
China is stepping up efforts to reassure U.S. corporate giants like Apple, Pfizer, and Mastercard of its economic potential, ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.
Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth ...
Investors with a lot of money to spend have taken a bearish stance on Eli Lilly LLY. And retail traders should know. We ...
Berenberg Bank analyst Kerry Holford maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on March 21 and set a price target ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback